US20030114503A1
(en)
*
|
1997-06-16 |
2003-06-19 |
Pfizer Inc. |
Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the treatment of cancer
|
CA2337800C
(en)
*
|
1998-07-06 |
2007-12-04 |
Janssen Pharmaceutica N.V. |
Farnesyl protein transferase inhibitors for treating arthropathies
|
WO2000012498A1
(en)
*
|
1998-08-27 |
2000-03-09 |
Pfizer Products Inc. |
Quinolin-2-one derivatives useful as anticancer agents
|
JP3495706B2
(ja)
*
|
1998-08-27 |
2004-02-09 |
ファイザー・プロダクツ・インク |
抗癌薬として有用なアルキニル置換キノリン−2−オン誘導体
|
EA200100766A1
(ru)
|
1999-02-11 |
2002-02-28 |
Пфайзер Продактс Инк. |
Хинолин-2-он замещенные гетероарильные производные, используемые в качестве противоопухолевых агентов
|
HN2000000266A
(es)
|
2000-01-21 |
2001-05-21 |
Pfizer Prod Inc |
Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
|
DE60130976T2
(de)
|
2000-02-24 |
2008-07-17 |
Janssen Pharmaceutica N.V. |
Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
|
JO2361B1
(en)
|
2000-06-22 |
2006-12-12 |
جانسين فارماسيوتيكا ان. في |
Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
|
ATE321038T1
(de)
|
2000-09-25 |
2006-04-15 |
Janssen Pharmaceutica Nv |
Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren
|
WO2002024683A1
(en)
|
2000-09-25 |
2002-03-28 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derivatives
|
AU2001293835A1
(en)
*
|
2000-09-25 |
2002-04-02 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
|
ES2313991T3
(es)
*
|
2000-09-25 |
2009-03-16 |
Janssen Pharmaceutica Nv |
Derivados de 6-heterociclilmetil-quinolina y quinazolina que inhiben la farnesil transferasa.
|
ES2328225T3
(es)
|
2000-11-21 |
2009-11-11 |
Janssen Pharmaceutica Nv |
Derivados benzoheterociclicos inhibidores de la farnesil-transferasa.
|
MXPA03005525A
(es)
|
2000-12-19 |
2003-10-06 |
Pfizer Prod Inc |
Formas cristalinas de sales de 2,3-dihidroxibutanodioato de 6-[(4-cloro -fenil)- hidroxi-(3 -metil-3h-imidazol -4-il)-metil] -4-(3-etinil-fenil) -1-metil-1h -quinolein-2 -ona, y metodo de produccion.
|
WO2002051835A1
(en)
*
|
2000-12-27 |
2002-07-04 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives
|
AU2002236813A1
(en)
*
|
2001-01-22 |
2002-07-30 |
Schering Corporation |
Treatment of malaria with farnesyl protein transferase inhibitors
|
JP4257698B2
(ja)
*
|
2001-03-12 |
2009-04-22 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
イミダゾール化合物の製造方法
|
US20020151563A1
(en)
*
|
2001-03-29 |
2002-10-17 |
Pfizer Inc. |
Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
|
AU2002257114A1
(en)
*
|
2001-04-06 |
2002-10-21 |
Schering Corporation |
Treatment of malaria with farsenyl protein transferase inhibitors
|
US20050165053A1
(en)
*
|
2001-06-04 |
2005-07-28 |
Cytovia, Inc. |
Substituted4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and analogs as activators of caspases and inducers of apoptosis and the use thereof
|
WO2003000266A1
(en)
|
2001-06-21 |
2003-01-03 |
Ariad Pharmaceuticals, Inc. |
Novel quinolines and uses thereof
|
US6740757B2
(en)
*
|
2001-08-29 |
2004-05-25 |
Pfizer Inc |
Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
|
WO2003051880A1
(en)
|
2001-12-19 |
2003-06-26 |
Janssen Pharmaceutica N.V. |
1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
|
EP1490065B1
(en)
|
2002-03-22 |
2007-06-13 |
Janssen Pharmaceutica N.V. |
Benzylimidazolyl substituted 2-quinolinone and quinazolinone derivatives for use as farnesyl transferase inhibitors
|
AU2003229688B2
(en)
|
2002-04-15 |
2009-07-30 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles
|
JP3814285B2
(ja)
*
|
2002-12-19 |
2006-08-23 |
ファイザー・インク |
眼疾患の治療に有用なプロテインキナーゼ阻害剤としての2−(1h−インダゾール−6−イルアミノ)−ベンズアミド化合物
|
JP4691041B2
(ja)
|
2003-11-20 |
2011-06-01 |
チルドレンズ ホスピタル メディカル センター |
Gtpアーゼ阻害剤および使用方法
|
US20050272722A1
(en)
*
|
2004-03-18 |
2005-12-08 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
BRPI0509580A
(pt)
*
|
2004-03-30 |
2007-11-27 |
Pfizer Prod Inc |
combinações de inibidores de transdução de sinal
|
CN101018780B
(zh)
*
|
2004-08-26 |
2012-01-11 |
辉瑞大药厂 |
作为蛋白激酶抑制剂的吡唑取代的氨基杂芳基化合物
|
ATE463486T1
(de)
|
2004-08-26 |
2010-04-15 |
Pfizer |
Enantiomerenreine aminoheteroaryl-verbindungen als proteinkinasehemmer
|
JP2008510792A
(ja)
*
|
2004-08-26 |
2008-04-10 |
ファイザー・インク |
タンパク質チロシンキナーゼ阻害剤としてのアミノヘテロアリール化合物
|
EP1815247B1
(en)
|
2004-11-05 |
2013-02-20 |
Janssen Pharmaceutica NV |
Therapeutic use of farnesyltransferase inhibitors and methods of monitoring the efficacy thereof
|
US20060107555A1
(en)
*
|
2004-11-09 |
2006-05-25 |
Curtis Marc D |
Universal snow plow adapter
|
US20060281788A1
(en)
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
|
US7826982B2
(en)
|
2005-07-29 |
2010-11-02 |
Children's Hospital Medical Center |
Method of identifying inhibitors using a 3-D structure of RAC-1 GTPASE
|
UA94060C2
(ru)
|
2005-09-07 |
2011-04-11 |
Эмджен Фримонт Инк. |
Моноклональное антитело, которое специфически связывает alk-1
|
WO2007035744A1
(en)
|
2005-09-20 |
2007-03-29 |
Osi Pharmaceuticals, Inc. |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
EP2545919A1
(en)
|
2005-12-23 |
2013-01-16 |
Link Medicine Corporation |
Treatment of synucleinopathies
|
TW200812615A
(en)
|
2006-03-22 |
2008-03-16 |
Hoffmann La Roche |
Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
|
JP5331681B2
(ja)
|
2006-04-20 |
2013-10-30 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
c−fmsキナーゼの阻害剤
|
MX2008013533A
(es)
|
2006-04-20 |
2009-01-15 |
Janssen Pharmaceutica Nv |
Compuestos heterociclicos como inhibidores de c-fms cinasa.
|
US8697716B2
(en)
|
2006-04-20 |
2014-04-15 |
Janssen Pharmaceutica Nv |
Method of inhibiting C-KIT kinase
|
EA200802058A1
(ru)
|
2006-05-09 |
2009-06-30 |
Пфайзер Продактс Инк. |
Производные циклоалкиламинокислот и их фармацевтические композиции
|
EP2441472B1
(en)
|
2006-08-21 |
2015-06-10 |
F. Hoffmann-La Roche AG |
Tumor therapy with an anti-VEGF antibody
|
WO2008112525A2
(en)
*
|
2007-03-09 |
2008-09-18 |
Link Medicine Corporation |
Treatment of lysosomal storage diseases
|
JO3240B1
(ar)
|
2007-10-17 |
2018-03-08 |
Janssen Pharmaceutica Nv |
c-fms مثبطات كيناز
|
US8232402B2
(en)
|
2008-03-12 |
2012-07-31 |
Link Medicine Corporation |
Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
|
DE102008022221A1
(de)
*
|
2008-05-06 |
2009-11-12 |
Universität des Saarlandes |
Inhibitoren der humanen Aldosteronsynthase CYP11B2
|
US20100331363A1
(en)
*
|
2008-11-13 |
2010-12-30 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
CA2743717A1
(en)
|
2008-11-13 |
2010-05-20 |
Link Medicine Corporation |
Azaquinolinone derivatives and uses thereof
|
US20110060005A1
(en)
*
|
2008-11-13 |
2011-03-10 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
US20120189641A1
(en)
|
2009-02-25 |
2012-07-26 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
WO2010099137A2
(en)
|
2009-02-26 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
In situ methods for monitoring the emt status of tumor cells in vivo
|
WO2010099363A1
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
JP2012519282A
(ja)
|
2009-02-27 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
US20110217309A1
(en)
|
2010-03-03 |
2011-09-08 |
Buck Elizabeth A |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
JP2013527748A
(ja)
|
2010-03-03 |
2013-07-04 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
インスリン様増殖因子1受容体キナーゼ阻害剤に対する抗癌反応の予測に役立つ生物学的マーカー
|
US20120214830A1
(en)
|
2011-02-22 |
2012-08-23 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
WO2012149014A1
(en)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
US9980942B2
(en)
|
2012-05-02 |
2018-05-29 |
Children's Hospital Medical Center |
Rejuvenation of precursor cells
|
EP2882757B1
(en)
|
2012-08-07 |
2016-10-05 |
Janssen Pharmaceutica, N.V. |
Process for the preparation of heterocyclic ester derivatives
|
JOP20180012A1
(ar)
|
2012-08-07 |
2019-01-30 |
Janssen Pharmaceutica Nv |
عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
|
AR094403A1
(es)
|
2013-01-11 |
2015-07-29 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos anti-her3
|
US10028503B2
(en)
|
2014-06-18 |
2018-07-24 |
Children's Hospital Medical Center |
Platelet storage methods and compositions for same
|
DK3277842T5
(da)
|
2015-08-17 |
2020-08-31 |
Kura Oncology Inc |
Fremgangsmåder til at behandle kræftpatienter med farnesyl-transferase-inhibitorer
|
JP6877429B2
(ja)
|
2015-12-03 |
2021-05-26 |
アジオス ファーマシューティカルズ, インコーポレイテッド |
Mtapヌル癌を処置するためのmat2a阻害剤
|
US20190119758A1
(en)
|
2016-04-22 |
2019-04-25 |
Kura Oncology, Inc. |
Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
|
US11124839B2
(en)
|
2016-11-03 |
2021-09-21 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
US11471538B2
(en)
|
2017-02-10 |
2022-10-18 |
INSERM (Institut National de la Santéet de la Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway
|
US10137121B2
(en)
|
2017-02-21 |
2018-11-27 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
EP3432883B1
(en)
|
2017-02-21 |
2021-07-28 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
BR112020002591A2
(pt)
|
2017-08-07 |
2020-07-28 |
Kura Oncology, Inc. |
método para o tratamento de câncer
|
US10806730B2
(en)
|
2017-08-07 |
2020-10-20 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
EP3873469A2
(en)
|
2018-11-01 |
2021-09-08 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
EP3897638A1
(en)
|
2018-12-21 |
2021-10-27 |
Kura Oncology, Inc. |
Therapies for squamous cell carcinomas
|
US20220142983A1
(en)
|
2019-03-01 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
TW202108170A
(zh)
|
2019-03-15 |
2021-03-01 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法
|
JP2022527495A
(ja)
|
2019-03-29 |
2022-06-02 |
クラ オンコロジー, インコーポレイテッド |
ファルネシルトランスフェラーゼ阻害剤による扁平上皮癌の治療方法
|
TW202102218A
(zh)
|
2019-04-01 |
2021-01-16 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基(farnesyl)轉移酶抑制劑治療癌症的方法
|
WO2020223583A1
(en)
|
2019-05-02 |
2020-11-05 |
Kura Oncology, Inc. |
Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
|
WO2021155006A1
(en)
|
2020-01-31 |
2021-08-05 |
Les Laboratoires Servier Sas |
Inhibitors of cyclin-dependent kinases and uses thereof
|